Antibody-drug conjugates (ADCs) continue to reshape the oncology landscape by combining the target specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs.

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

With ongoing advancements in drug engineering and fresh biologic insight into mechanisms of drug action, the ADC field is still early in its evolution. Despite this, there are over a 100 new ADCs in ...

The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its ...